Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Humana Inc.

9.6% sales growth and 30.35% return on equity

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States.

Humana Inc.’s sales growth this year is expected to be 17.2% and 8.8% for next year.

Year-on-year quarterly revenue growth grew by 23.6%, now sitting on 74.39B for the twelve trailing months.

Humana Inc.’s sales growth for the next quarter is 9.6%. The company’s growth estimates for the current quarter and the next is a negative 203.9% and 8.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.35%.

Volatility

Humana Inc.’s last day, last week, and last month’s average volatility was a negative 2.50%, a positive 1.29%, and a positive 0.32%, respectively.

Humana Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.65%, 4.24%, and 2.68%, respectively.

Humana Inc.’s Stock Yearly Top and Bottom Value

Humana Inc.’s stock is valued at $436.77 at 01:22 EST, below its 52-week high of $474.70 and way higher than its 52-week low of $208.25.

Humana Inc.’s Moving Average

Humana Inc.’s worth is above its 50-day moving average of $405.18 and higher than its 200-day moving average of $408.01.

2. Select Bancorp, Inc.

12.3% sales growth and 3.42% return on equity

Select Bancorp, Inc. operates as the bank holding company for Select Bank & Trust Company that provides banking services to individuals and small to medium-sized businesses.

Select Bancorp, Inc.’s sales growth this year is expected to be 7% and 6.3% for next year.

Year-on-year quarterly revenue growth grew by 0.9%, now sitting on 48.17M for the twelve trailing months.

Select Bancorp, Inc.’s sales growth for the next quarter is 12.3%. The company’s growth estimates for the present quarter and the next is a negative 18.8% and 166.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.42%.

Volatility

Select Bancorp, Inc.’s last day, last week, and last month’s average volatility was a negative 0.10%, a positive 1.77%, and a positive 0.26%, respectively.

Select Bancorp, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.11%, 4.42%, and 2.95%, respectively.

Select Bancorp, Inc.’s Stock Yearly Top and Bottom Value

Select Bancorp, Inc.’s stock is valued at $9.85 at 01:22 EST, way below its 52-week high of $12.01 and way above its 52-week low of $5.98.

Select Bancorp, Inc.’s Moving Average

Select Bancorp, Inc.’s value is above its 50-day moving average of $9.52 and way higher than its 200-day moving average of $8.22.

3. Nelnet, Inc.

20.4% sales growth and 6.72% return on equity

Nelnet, Inc. engages in loan servicing, communications, and education technology, services, and payment processing businesses worldwide.

Nelnet, Inc.’s sales growth this year is expected to be 44.5% and a negative 16.4% for next year.

Year-on-year quarterly revenue growth grew by 14.5%, now sitting on 1.1B for the twelve trailing months.

Nelnet, Inc.’s sales growth for the next quarter is 20.4%. The company’s growth estimates for the current quarter and the next is 406.2% and 291.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.72%.

Volatility

Nelnet, Inc.’s last day, last week, and last month’s average volatility was a negative 1.43%, a positive 0.19%, and a positive 0.15%, respectively.

Nelnet, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.67%, 3.26%, and 2.46%, respectively.

Nelnet, Inc.’s Stock Yearly Top and Bottom Value

Nelnet, Inc.’s stock is valued at $71.90 at 01:22 EST, below its 52-week high of $74.21 and way higher than its 52-week low of $36.70.

Nelnet, Inc.’s Moving Average

Nelnet, Inc.’s worth is higher than its 50-day moving average of $69.51 and way above its 200-day moving average of $63.86.

4. Middlefield Banc Corp.

9.5% sales growth and 6.48% return on equity

Middlefield Banc Corp. operates as the bank holding company for The Middlefield Banking Company that provides various commercial banking services to small and medium-sized businesses, professionals, small business owners, and retail customers in northeastern and central Ohio.

Middlefield Banc Corp.’s sales growth this year is expected to be 9% and a negative 4.4% for next year.

Year-on-year quarterly revenue growth declined by 21%, now sitting on 39.91M for the twelve trailing months.

Middlefield Banc Corp.’s sales growth for the next quarter is 9.5%. The company’s growth estimates for the ongoing quarter and the next is 4.1% and 162.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.48%.

Volatility

Middlefield Banc Corp.’s last day, last week, and last month’s average volatility was a negative 1.31%, a negative 0.36%, and a positive 0.06%, respectively.

Middlefield Banc Corp.’s last day, last week, and last month’s high and low average amplitude percentage was 3.23%, 2.59%, and 4.09%, respectively.

Middlefield Banc Corp.’s Stock Yearly Top and Bottom Value

Middlefield Banc Corp.’s stock is valued at $21.94 at 01:22 EST, way below its 52-week high of $26.19 and way higher than its 52-week low of $12.00.

Middlefield Banc Corp.’s Moving Average

Middlefield Banc Corp.’s value is higher than its 50-day moving average of $21.77 and way higher than its 200-day moving average of $19.89.

5. A-Mark Precious Metals, Inc.

10.6% sales growth and 57.28% return on equity

A-Mark Precious Metals, Inc., together with its subsidiaries, operates as a precious metals trading company.

A-Mark Precious Metals, Inc.’s sales growth this year is anticipated to be 14.3% and a negative 9.6% for next year.

Year-on-year quarterly revenue growth grew by 26%, now sitting on 5.85B for the twelve trailing months.

A-Mark Precious Metals, Inc.’s sales growth is a negative 0% for the current quarter and 10.6% for the next. The company’s growth estimates for the present quarter and the next is 505.9% and negative -51.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 57.28%.

Volatility

A-Mark Precious Metals, Inc.’s last day, last week, and last month’s average volatility was a negative 1.10%, a positive 1.96%, and a negative 0.31%, respectively.

A-Mark Precious Metals, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 6.06%, 5.11%, and 5.39%, respectively.

A-Mark Precious Metals, Inc.’s Stock Yearly Top and Bottom Value

A-Mark Precious Metals, Inc.’s stock is valued at $28.24 at 01:22 EST, way under its 52-week high of $37.60 and way higher than its 52-week low of $7.47.

A-Mark Precious Metals, Inc.’s Moving Average

A-Mark Precious Metals, Inc.’s worth is below its 50-day moving average of $29.00 and higher than its 200-day moving average of $27.89.

6. Neurocrine Biosciences, Inc.

15.9% sales growth and 13.55% return on equity

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States.

Neurocrine Biosciences, Inc.’s sales growth this year is anticipated to be 34.5% and 16.4% for next year.

Year-on-year quarterly revenue growth grew by 16.4%, now sitting on 1.04B for the twelve trailing months.

Neurocrine Biosciences, Inc.’s sales growth for the next quarter is 15.9%. The company’s growth estimates for the current quarter and the next is 60% and 25.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.55%.

Volatility

Neurocrine Biosciences, Inc.’s last day, last week, and last month’s average volatility was a negative 1.60%, a positive 2.91%, and a positive 0.90%, respectively.

Neurocrine Biosciences, Inc.’s last day, last week, and last month’s high and low average amplitude percentage was 3.67%, 5.11%, and 3.64%, respectively.

Neurocrine Biosciences, Inc.’s Stock Yearly Top and Bottom Value

Neurocrine Biosciences, Inc.’s stock is valued at $110.30 at 01:22 EST, way under its 52-week high of $136.26 and way higher than its 52-week low of $72.14.

Neurocrine Biosciences, Inc.’s Moving Average

Neurocrine Biosciences, Inc.’s worth is way higher than its 50-day moving average of $96.51 and higher than its 200-day moving average of $106.54.

7. Laboratory Corporation of America Holdings

28.4% sales growth and 10.9% return on equity

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide.

Laboratory Corporation of America Holdings’s sales growth this year is anticipated to be 16.3% and 3.7% for next year.

Year-on-year quarterly revenue growth grew by 33%, now sitting on 12.44B for the twelve trailing months.

Laboratory Corporation of America Holdings’s sales growth for the next quarter is 28.4%. The company’s growth estimates for the present quarter and the next is 155.9% and 141.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.9%.

Volatility

Laboratory Corporation of America Holdings’s last day, last week, and last month’s average volatility was a negative 2.22%, a positive 0.97%, and a positive 0.27%, respectively.

Laboratory Corporation of America Holdings’s last day, last week, and last month’s high and low average amplitude percentage was 4.29%, 3.19%, and 2.09%, respectively.

Laboratory Corporation of America Holdings’s Stock Yearly Top and Bottom Value

Laboratory Corporation of America Holdings’s stock is valued at $213.55 at 01:22 EST, under its 52-week high of $220.35 and way higher than its 52-week low of $98.02.

Laboratory Corporation of America Holdings’s Moving Average

Laboratory Corporation of America Holdings’s worth is higher than its 50-day moving average of $203.00 and way above its 200-day moving average of $191.79.

LEAVE A REPLY

Please enter your comment!
Please enter your name here